Imerge Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Imerge Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Imerge Trial Today - Breaking & Trending Today

$Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study - Vimarsana News$

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Published: January 10, 2024

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

Source: onclive.com

Related Topics:

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Published: October 5, 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Source: onclive.com

Related Topics:

Future Treatment Strategies Recent Data New Agents Lower Risk Mds Lower Risk Myelodysplastic Syndrome Myelodysplastic Syndrome Clinical Implications Transfusion Independence Imerge Trial

EMA Validates MAA for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

Published: October 3, 2023

The European Medicines Agency has validated the marketing authorization application for the use of imetelstat in the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

Source: onclive.com

Related Topics:

Geron Corporation European Medicines Agency Transfusion Dependent Anemia In Patients With Lower Risk Myelodysplastic Syndrome Imerge Trial Johna Scarlett

Data Updates From the IMerge Trial

Published: August 14, 2023

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.

Source: targetedonc.com

Dr Zeidan on Imetelstat in Lower-risk MDS

Published: June 3, 2023

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.

Source: onclive.com

Related Topics:

Samer Zeidan Yale Cancer Center Clinical Trials Office Protocol Review Committee Disease Aligned Research Team For Leukemias Hematology Research Seminar Series Early Therapeutics Research Disease Aligned Research Team Myeloid Malignancies Executive Committee Imerge Trial Patients With Transfusion Dependent Lower Risk Myelodysplastic Syndrome

Page 2 Page 3 Page 4 Page 5